# Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

> **NCT00133991** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 23 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** Filgrastim
- **BIOLOGICAL:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Prednisone
- **DRUG:** Hydrocortisone
- **DRUG:** Vincristine
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT00133991
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2011-08
- **Final completion:** 2013-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133991, "Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00133991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*